Dr. Gibstein suggested that time would tell if the protection is durable, and if complications can be directly attributable to the vaccine.
Tagged: Pharmaceutical Industry
I talked with Media Relations spokesperson, Pam Eisele, about the vaccine. I submitted a series of questions for the company to answer via e-mail, referencing red flags that had come up in my research. All my queries were responded to, and Eisele offered to put me in touch with a clinical researcher if I required further explanations.